Cambridge-based startup Repositive has closed a £2.5m Series A funding round.
This brings the total raised to date by the human genomic research data portal to £3.3m.
Fiona Nielsen, CEO of Repositive, said: “This investment will allow Repositive to expand its commercial offering through the development of premium features for our fast growing community of platform users worldwide.”
She went on to say the firm will invest further in “expanding the range of data sources on our platform and developing further commercial products and services for the genomics R&D industry”.
The Repositive platform launched in September 2016 and has since grown to over one million data sets, with its global user base expanding across pharma, biotech and academia.
Lennart Hergel, investment director at Ananda Social Venture Fund, said: “Repositive is unique in identifying, providing access and democratising genomic data without ethical compromise.
“We believe that this will reduce time and cost for diagnostics and drug development, therefore enabling better and affordable access to new and personalised therapies for patients.”